Market Cap 567.86M
Revenue (ttm) 40,000.00
Net Income (ttm) -88.09M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -220,225.00%
Debt to Equity Ratio 0.15
Volume 3,127,200
Avg Vol 3,816,240
Day's Range N/A - N/A
Shares Out 194.47M
Stochastic %K 28%
Beta 0.21
Analysts Strong Sell
Price Target $16.05

Company Profile

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Industry: Biotechnology
Sector: Healthcare
Phone: 240 654 1450
Address:
910 Clopper Road, Suite 201S, Gaithersburg, United States
FocusedShareholderValue
FocusedShareholderValue Jun. 6 at 3:20 PM
$ALT over under on kissing $2.50 close day before gsco, then get a rerate from them over the weekend and we 2x+ that Monday assuming management doesn’t flop?
0 · Reply
Jacked_Nicholson_is_back
Jacked_Nicholson_is_back Jun. 6 at 2:58 PM
$ALT This what ChatGPT thinks the month of June could look like…
0 · Reply
jerzypawlik
jerzypawlik Jun. 6 at 2:54 PM
$ALT Buyout in range $25-$35 .These numbers are very realistic and reasonable. Valuation on market demand, and benefits provided. Hang in there everyone, it's coming.
0 · Reply
Jacked_Nicholson_is_back
Jacked_Nicholson_is_back Jun. 6 at 2:51 PM
$ALT $ALT For me, the strongest AUD-related signals from the conference were: * “good solid bet” * semaglutide data are “validating” * discussion of FDA interactions after readout * willingness to seek funding/partnerships for next-stage development Taken together, management sounded much more optimistic on AUD than I initially thought… We deserve to go North with all the pain we went through… But we all remember June 26 2025…
0 · Reply
StockDark
StockDark Jun. 6 at 1:04 PM
$ALT final shake out??? Hopefully rerate starts from July/August.
0 · Reply
Alex1710
Alex1710 Jun. 6 at 12:27 PM
$ALT $1.90 will be a good entry point cos this is where it goes
2 · Reply
GreenEnergy7B
GreenEnergy7B Jun. 6 at 12:19 PM
$ALT And here is the valuation you can expect on phs3 approval + different scenarios for AUD + ALD
0 · Reply
GreenEnergy7B
GreenEnergy7B Jun. 6 at 12:18 PM
$ALT Here is the valuation you can expect on phs3 approval
0 · Reply
Alexandre_300
Alexandre_300 Jun. 6 at 9:33 AM
$ALT I found the prior Jan 2026 Code of Business Conduct & Ethics and compared it with the updated May 27, 2026 version — same day as EASL Day 1. Key changes: 1. Scope expanded Old: “directors, officers and employees” New: “directors, officers, employees and certain consultants, contractors and advisors acting on behalf of the Company.” 2. CLO now more central Old language focused on a generic “Compliance Officer.” New version names the “Chief Legal Officer or Compliance Officer” as the key authority. 3. Insider trading/confidentiality rules now apply to a broader group of “Covered Individuals,” including external advisors/contractors acting for ALT. Why it matters: this does not prove M&A, but the timing around EASL + PERFORMA Phase 3 startup is notable. It looks consistent with a late-stage compliance buildout involving CROs, vendors, consultants, advisors and sensitive clinical/regulatory info. Not investment advice. NFA. DYOR.
1 · Reply
JuggernautRaider
JuggernautRaider Jun. 6 at 8:39 AM
$TNXP $PFE $CCCC $ALT @Willy_Nilly it is some burnt out managed care organization physician whi got paid a couple hundred bucks by alphasense for an interview But yea… old Pfizer should be buying Tonix, C4, and AltImmune… or some other big pharma will 🤫
0 · Reply
Latest News on ALT
Altimmune to Participate in Upcoming Investor Conferences

May 27, 2026, 8:30 AM EDT - 10 days ago

Altimmune to Participate in Upcoming Investor Conferences


Altimmune Slides: Corporate presentation

May 14, 2026, 7:00 AM EDT - 23 days ago

Altimmune Slides: Corporate presentation


Altimmune price target lowered to $11 from $14 at Citizens

2026-05-14T09:47:49.000Z - 23 days ago

Altimmune price target lowered to $11 from $14 at Citizens


Altimmune Earnings Call Transcript: Q1 2026

May 13, 2026, 8:30 AM EDT - 24 days ago

Altimmune Earnings Call Transcript: Q1 2026


Altimmune Earnings release: Q1 2026

May 13, 2026, 8:30 AM EDT - 24 days ago

Altimmune Earnings release: Q1 2026


Altimmune Quarterly report: Q1 2026

May 13, 2026, 8:30 AM EDT - 24 days ago

Altimmune Quarterly report: Q1 2026


Altimmune reports Q1 EPS (18c), consensus (25c)

2026-05-13T11:59:47.000Z - 24 days ago

Altimmune reports Q1 EPS (18c), consensus (25c)


Altimmune management to meet with Piper Sandler

2026-04-27T19:56:05.000Z - 5 weeks ago

Altimmune management to meet with Piper Sandler


Altimmune upgraded to Neutral from Sell at Goldman Sachs

2026-04-24T09:16:13.000Z - 6 weeks ago

Altimmune upgraded to Neutral from Sell at Goldman Sachs


Altimmune 64.25M share Spot Secondary priced at $3.00

2026-04-23T11:06:36.000Z - 6 weeks ago

Altimmune 64.25M share Spot Secondary priced at $3.00


Altimmune announces common stock offering, no amount given

2026-04-22T20:28:30.000Z - 6 weeks ago

Altimmune announces common stock offering, no amount given


Altimmune Transcript: AGM 2026

Apr 16, 2026, 8:30 AM EDT - 7 weeks ago

Altimmune Transcript: AGM 2026


Altimmune initiated with a Buy at Truist

2026-03-18T20:00:19.000Z - 2 months ago

Altimmune initiated with a Buy at Truist


Altimmune Proxy statement: Proxy Filing

Mar 17, 2026, 8:00 AM EDT - 2 months ago

Altimmune Proxy statement: Proxy Filing


Altimmune Transcript: Leerink Global Healthcare Conference 2026

Mar 11, 2026, 9:20 AM EDT - 3 months ago

Altimmune Transcript: Leerink Global Healthcare Conference 2026


Altimmune Transcript: The Citizens Life Sciences Conference 2026

Mar 10, 2026, 2:15 PM EDT - 3 months ago

Altimmune Transcript: The Citizens Life Sciences Conference 2026


Altimmune Slides: Corporate presentation

Mar 9, 2026, 7:00 AM EDT - 3 months ago

Altimmune Slides: Corporate presentation


Altimmune price target lowered to $13 from $18 at B. Riley

2026-03-06T13:40:07.000Z - 3 months ago

Altimmune price target lowered to $13 from $18 at B. Riley


Altimmune Proxy statement: Proxy Filing

Mar 6, 2026, 7:00 AM EST - 3 months ago

Altimmune Proxy statement: Proxy Filing


Altimmune Earnings Call Transcript: Q4 2025

Mar 5, 2026, 8:30 AM EST - 3 months ago

Altimmune Earnings Call Transcript: Q4 2025


Altimmune Annual report: Q4 2025

Mar 5, 2026, 8:30 AM EST - 3 months ago

Altimmune Annual report: Q4 2025


Altimmune Earnings release: Q4 2025

Mar 5, 2026, 8:30 AM EST - 3 months ago

Altimmune Earnings release: Q4 2025


Altimmune reports Q4 EPS (27c), consensus (24c)

2026-03-05T12:14:56.000Z - 3 months ago

Altimmune reports Q4 EPS (27c), consensus (24c)


Altimmune management to meet with Piper Sandler

2026-02-20T14:12:05.000Z - 3 months ago

Altimmune management to meet with Piper Sandler


Altimmune initiated with a Buy at Titan Partners

2026-02-13T14:55:31.000Z - 4 months ago

Altimmune initiated with a Buy at Titan Partners


Altimmune (ALT) Raises $75M to Boost Obesity Drug Pipeline

2026-01-28T08:09:07.000Z - 4 months ago

Altimmune (ALT) Raises $75M to Boost Obesity Drug Pipeline

LLY NVO


Altimmune prices $75M registered direct offering

2026-01-28T05:35:22.000Z - 4 months ago

Altimmune prices $75M registered direct offering


Altimmune Transcript: Study Result

Dec 19, 2025, 8:00 AM EST - 6 months ago

Altimmune Transcript: Study Result


Altimmune Press release: Study Result

Dec 19, 2025, 8:00 AM EST - 6 months ago

Altimmune Press release: Study Result


Altimmune Slides: Study Result

Dec 19, 2025, 8:00 AM EST - 6 months ago

Altimmune Slides: Study Result


Altimmune Announces CEO Transition and Succession Plan

Dec 1, 2025, 7:30 AM EST - 6 months ago

Altimmune Announces CEO Transition and Succession Plan


Altimmune Registration statement: Registration Filing

Nov 13, 2025, 7:00 AM EST - 7 months ago

Altimmune Registration statement: Registration Filing


Altimmune Transcript: Stifel 2025 Healthcare Conference

Nov 12, 2025, 10:00 AM EST - 7 months ago

Altimmune Transcript: Stifel 2025 Healthcare Conference


Altimmune Slides: Corporate Presentation

Nov 6, 2025, 4:00 PM EST - 7 months ago

Altimmune Slides: Corporate Presentation


Altimmune Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:30 AM EST - 7 months ago

Altimmune Earnings Call Transcript: Q3 2025


Altimmune Quarterly report: Q3 2025

Nov 6, 2025, 8:30 AM EST - 7 months ago

Altimmune Quarterly report: Q3 2025


Altimmune Earnings release: Q3 2025

Nov 6, 2025, 8:30 AM EST - 7 months ago

Altimmune Earnings release: Q3 2025


Altimmune Registration statement: Registration Filing

Nov 6, 2025, 7:00 AM EST - 7 months ago

Altimmune Registration statement: Registration Filing


Altimmune to Participate in Two Upcoming Investor Conferences

Nov 5, 2025, 7:30 AM EST - 7 months ago

Altimmune to Participate in Two Upcoming Investor Conferences


Altimmune Transcript: Stifel Virtual Cardiometabolic Forum

Sep 30, 2025, 10:30 AM EDT - 8 months ago

Altimmune Transcript: Stifel Virtual Cardiometabolic Forum


Altimmune Transcript: AGM 2025

Sep 25, 2025, 8:30 AM EDT - 9 months ago

Altimmune Transcript: AGM 2025


FocusedShareholderValue
FocusedShareholderValue Jun. 6 at 3:20 PM
$ALT over under on kissing $2.50 close day before gsco, then get a rerate from them over the weekend and we 2x+ that Monday assuming management doesn’t flop?
0 · Reply
Jacked_Nicholson_is_back
Jacked_Nicholson_is_back Jun. 6 at 2:58 PM
$ALT This what ChatGPT thinks the month of June could look like…
0 · Reply
jerzypawlik
jerzypawlik Jun. 6 at 2:54 PM
$ALT Buyout in range $25-$35 .These numbers are very realistic and reasonable. Valuation on market demand, and benefits provided. Hang in there everyone, it's coming.
0 · Reply
Jacked_Nicholson_is_back
Jacked_Nicholson_is_back Jun. 6 at 2:51 PM
$ALT $ALT For me, the strongest AUD-related signals from the conference were: * “good solid bet” * semaglutide data are “validating” * discussion of FDA interactions after readout * willingness to seek funding/partnerships for next-stage development Taken together, management sounded much more optimistic on AUD than I initially thought… We deserve to go North with all the pain we went through… But we all remember June 26 2025…
0 · Reply
StockDark
StockDark Jun. 6 at 1:04 PM
$ALT final shake out??? Hopefully rerate starts from July/August.
0 · Reply
Alex1710
Alex1710 Jun. 6 at 12:27 PM
$ALT $1.90 will be a good entry point cos this is where it goes
2 · Reply
GreenEnergy7B
GreenEnergy7B Jun. 6 at 12:19 PM
$ALT And here is the valuation you can expect on phs3 approval + different scenarios for AUD + ALD
0 · Reply
GreenEnergy7B
GreenEnergy7B Jun. 6 at 12:18 PM
$ALT Here is the valuation you can expect on phs3 approval
0 · Reply
Alexandre_300
Alexandre_300 Jun. 6 at 9:33 AM
$ALT I found the prior Jan 2026 Code of Business Conduct & Ethics and compared it with the updated May 27, 2026 version — same day as EASL Day 1. Key changes: 1. Scope expanded Old: “directors, officers and employees” New: “directors, officers, employees and certain consultants, contractors and advisors acting on behalf of the Company.” 2. CLO now more central Old language focused on a generic “Compliance Officer.” New version names the “Chief Legal Officer or Compliance Officer” as the key authority. 3. Insider trading/confidentiality rules now apply to a broader group of “Covered Individuals,” including external advisors/contractors acting for ALT. Why it matters: this does not prove M&A, but the timing around EASL + PERFORMA Phase 3 startup is notable. It looks consistent with a late-stage compliance buildout involving CROs, vendors, consultants, advisors and sensitive clinical/regulatory info. Not investment advice. NFA. DYOR.
1 · Reply
JuggernautRaider
JuggernautRaider Jun. 6 at 8:39 AM
$TNXP $PFE $CCCC $ALT @Willy_Nilly it is some burnt out managed care organization physician whi got paid a couple hundred bucks by alphasense for an interview But yea… old Pfizer should be buying Tonix, C4, and AltImmune… or some other big pharma will 🤫
0 · Reply
BuddyBoy6975
BuddyBoy6975 Jun. 6 at 5:57 AM
$ALT Interesting… Daily option volume re: Sept/Nov/Jan’s is disappearing rapidly. From my chair Tells me me the PIG is in the POT
0 · Reply
Dazedconfused12
Dazedconfused12 Jun. 6 at 5:03 AM
0 · Reply
StockDark
StockDark Jun. 6 at 4:38 AM
$ALT First window of M&A Begins soon.
0 · Reply
BuddyBoy6975
BuddyBoy6975 Jun. 6 at 4:23 AM
$ALT Mike, SP doesn’t mean a dam thing until those we call Bigs let it run. Just know you’re… IN THE GROUND FLOOR If you’re in Equity. Take a vacay. Go do something. Stop watching it every day. CUZ ur in the Ground Floor
0 · Reply
BuddyBoy6975
BuddyBoy6975 Jun. 6 at 2:52 AM
$ALT Is that a serious question…? 🙄🙄 How does June 22nd @ 9:38am sound. Book it Dano 🤣🤣🤣🤣🤣🤣🤣 One for THE AGES :)
1 · Reply
Colineskibashian
Colineskibashian Jun. 6 at 1:48 AM
$ALT When would we see a GS rerate? Is there a set time they rerate stocks or would it be this upcoming Monday?
1 · Reply
jerzypawlik
jerzypawlik Jun. 6 at 1:46 AM
$ALT And don't listen to those shorts, pretending to be bulls. Theirs days are counted. Tuts don't invest to lose money. On any good news they will at least triple the share price.
1 · Reply
jerzypawlik
jerzypawlik Jun. 6 at 1:43 AM
$ALT Nobody gives a s...t about GS rating. They intentionally gave low pt, so could robbed retailers,so tutes ,and their minions could load cheap shares. They might succeed with some dumb retailers, but the smartest ones won't ever sell at this current price. The average target sp is over $16,some even give close to $30, and is not even close what this company will be worth in the future. The whole market today was a bloodbath, and will rebound next week. Many good bio, and technology companies lost 8%-15% MC. Today was the worst day of the year, and correction like this is normal. So bulls enjoy your weekend and don't be discouraged. We have the best read out, and prospects of taking it to the market. Outcome will be partnership, or buyout either way we'll make lots of money here.
0 · Reply
mALTraa
mALTraa Jun. 6 at 1:00 AM
$ALT The last nail in the coffin could be a GS downgrade to “Sell” after the conference. If that happens, recovery could become extremely difficult, so be prepared for that possibility. At the same time, it does feel like ALT was invited to this conference for a reason, possibly at someone’s behest. Hopefully management is well prepared and ready to handle the scrutiny. That said, the upside scenario is still massive. Any genuine upgrade could easily send the stock well above $10. Also, if GS issues a PT of $10 or higher, the average PT across all analysts would move well above $20.
1 · Reply
jayessbee
jayessbee Jun. 6 at 12:57 AM
$ALT IMO, those could have been to help convince you to vote on approving the increase of shares— so you’d feel more confident that they wouldn’t immediately dilute.
1 · Reply
Jacked_Nicholson_is_back
Jacked_Nicholson_is_back Jun. 6 at 12:29 AM
0 · Reply
Chalutz
Chalutz Jun. 5 at 11:53 PM
$ALT Share buyback programs have to be registered with the SEC. The registration specifies the total $ amount of the share buyback and time period it is in effect. Understand the Co, ALT, has sole and absolute discretion of whether or not to ever repurchase a single share. It is an OPTION not an OBLIGATION. DURSO sold 20 million shares in Jan 2026 17+ million to Alyeska at $4.40. Plus $8.9 million via ATM. The threat of reducing OS supports price and repurchased shares can be used for a PARTNERSHIP, cover the warrants etc. REGISTER a $100 million buyback with SEC now to be ready before we hit $1 plus GET new CEO!
0 · Reply